– UK, Cambridge – KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced the appointment of Bethany Sensenig to its Board of Directors, effective as of October 1, 2025.
Bethany Sensenig has also joined the Audit Committee.
About Bethany L. Sensenig
Bethany Sensenig is an accomplished healthcare executive and experienced board member with over 20 years of leadership in finance, corporate strategy, and commercial operations. She currently serves as CFO (CFO) and Head of Operations at Radius Health, Inc., a commercial-stage biopharmaceutical company focused on bone health. She previously held roles as CFO and Interim CEO at 9 Meters Biopharma, Inc., a clinical-stage company focused on rare diseases. Before that, Ms. Sensenig was the CFO and Head of US Operations at Minovia Therapeutics, a clinical-stage biotech company developing innovative cell therapies for rare mitochondrial diseases. Before her CFO roles, Ms. Sensenig spent 13 years at Biogen Inc., a multinational biotechnology company, where she rose to VP of Finance and Commercial Operations, overseeing $1B+ in revenue across 30 countries. She is also a member of the Board of Directors and the Audit Committee of Supernus Pharmaceuticals, Inc., a commercial-stage pharmaceutical company.
Bethany Sensenig earned her B.S. in Accounting and Business Management from Montreat College and an M.B.A. from Western Carolina University.
About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world.
For more: https://www.kalvista.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.